Risankizumab in Children With Crohn's Disease (RisaKids)

Co-primary outcomes: Complete remission at end of remission (weeks 12 and week 54)

The goal of this observational study is to to prospectively explore the real life short (12
 weeks) and longer term (54 weeks) clinical, biochemical and endoscopic outcomes of
 risankizumab in pediatric CD.
 
 This is a 1-year prospective multi-center cohort study of children commencing on risankizumab
 for pediatric CD with 2 years extension for long-term follow-up. The investigators will
 record clinical manifestations, blood markers and fecal calprotectin, with monitoring for
 safety signals including infusion and injection site reactions, pyrexia and infections at
 various intervals as outlined below. The investigators will also include calprotectin
 monitoring and fecal sample collection for microbiome and serum samples for drug levels.
 According to available budget, the investigators will also collect fecal and serum samples
 for metabolome. Samples collection is optional, thus failure of bio-samples collection will
 not exclude patients from the study.